Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (64) 64
index medicus (62) 62
male (50) 50
female (38) 38
middle aged (31) 31
oncology (31) 31
adult (27) 27
aged (21) 21
animals (21) 21
lung neoplasms - drug therapy (18) 18
chemotherapy (17) 17
lung cancer (16) 16
treatment outcome (16) 16
cancer (13) 13
carcinoma, non-small-cell lung - drug therapy (13) 13
disease-free survival (13) 13
medicine (13) 13
mice (12) 12
research (12) 12
antineoplastic combined chemotherapy protocols - therapeutic use (11) 11
genetic aspects (11) 11
lung neoplasms - pathology (11) 11
lung cancer, non-small cell (10) 10
medical research (10) 10
gene expression (9) 9
genes (9) 9
magnetic resonance imaging (9) 9
prognosis (9) 9
research article (9) 9
aged, 80 and over (8) 8
analysis (8) 8
carcinoma, non-small-cell lung - genetics (8) 8
carcinoma, non-small-cell lung - pathology (8) 8
care and treatment (8) 8
kaplan-meier estimate (8) 8
lung neoplasms - genetics (8) 8
multidisciplinary sciences (8) 8
mutation (8) 8
rats (8) 8
science (8) 8
clinical trials (7) 7
endocrinology & metabolism (7) 7
expression (7) 7
gefitinib (7) 7
genomes (7) 7
oxidative stress (7) 7
studies (7) 7
tumors (7) 7
antineoplastic agents - therapeutic use (6) 6
biochemistry & molecular biology (6) 6
cell biology (6) 6
diagnosis (6) 6
disease progression (6) 6
erlotinib (6) 6
lung neoplasms - mortality (6) 6
neoplasm staging (6) 6
patients (6) 6
phase-ii trial (6) 6
survival analysis (6) 6
therapy (6) 6
antineoplastic agents - adverse effects (5) 5
biology (5) 5
carboplatin - administration & dosage (5) 5
carcinoma, non-small-cell lung - mortality (5) 5
case-control studies (5) 5
development and progression (5) 5
double-blind method (5) 5
drug therapy (5) 5
evolution (5) 5
genomics (5) 5
insulin resistance (5) 5
medicine, general & internal (5) 5
metastasis (5) 5
oncology, experimental (5) 5
rats, sprague-dawley (5) 5
respiratory system (5) 5
time factors (5) 5
transcription (5) 5
3t3-l1 cells (4) 4
abridged index medicus (4) 4
adipogenesis - genetics (4) 4
aids (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (4) 4
article subject (4) 4
cancer therapies (4) 4
carboplatin (4) 4
carcinoma, non-small-cell lung - metabolism (4) 4
cell line, tumor (4) 4
chinese (4) 4
combination (4) 4
economic conditions (4) 4
engineering, biomedical (4) 4
free radicals (4) 4
gene (4) 4
gene-expression (4) 4
genetic association studies (4) 4
genetic predisposition to disease (4) 4
glucose (4) 4
hiv (4) 4
hospitals (4) 4
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (9) 9
UTL at Downsview - May be requested (2) 2
UofT at Mississauga - Stacks (2) 2
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Gerstein Science - Stacks (1) 1
Trinity College (John W Graham) - Reference (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Emerging treatment paradigms for brain metastasis in non-small-cell lung cancer: An overview of the current landscape and challenges ahead
by Ulahannan, D and Khalifa, J and Faivre-Finn, C and Lee, Siow-Ming
Annals of Oncology, ISSN 0923-7534, 12/2017, Volume 28, Issue 12, pp. 2923 - 2931
Advances in the last decade in genomic profiling and the identification of druggable targets amenable to biological agents have transformed the management and... 
Non-small-cell lung cancer | Personalized medicine | Radiotherapy | Brain metastasis | PHASE-II | RANDOMIZED-TRIAL | DOSE WEEKLY ERLOTINIB | personalized medicine | RADIATION-THERAPY | TYROSINE KINASE INHIBITORS | ANAPLASTIC LYMPHOMA KINASE | ONCOLOGY | RECURSIVE PARTITIONING ANALYSIS | LEPTOMENINGEAL METASTASES | STEREOTACTIC RADIOSURGERY BOOST | radiotherapy | brain metastasis | SURGICAL RESECTION | non-small-cell lung cancer | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Brain Neoplasms - secondary | Carcinoma, Non-Small-Cell Lung - genetics | Humans | Lung Neoplasms - pathology | Antineoplastic Agents - administration & dosage | Carcinoma, Non-Small-Cell Lung - drug therapy | Brain Neoplasms - drug therapy | Molecular Targeted Therapy | Randomized Controlled Trials as Topic
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3)
by Forster, Martin and Hackshaw, Allan and De Pas, Tommaso and Cobo, Manuel and Garrido, Pilar and Summers, Yvonne and Dingemans, Anne-Marie C and Flynn, Michael and Schnell, David and von Wangenheim, Ute and Loembé, Arsene-Bienvenu and Kaiser, Rolf and Lee, Siow Ming
Lung Cancer, ISSN 0169-5002, 06/2018, Volume 120, pp. 27 - 33
There are limited treatment options for squamous non-small cell lung cancer (sqNSCLC) and prognosis remains poor. The safety and pharmacokinetics (PK) of... 
Nintedanib | Squamous | Non-small cell lung cancer | Medicine, Experimental | Medical research | Lung cancer, Small cell | Care and treatment | Lung cancer, Non-small cell
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Erlotinib plus concurrent whole-brain radiation therapy for nonsmall cell lung cancers patients with multiple brain metastases
by Ulahannan, Danny and Lee, Siow-Ming
Translational Lung Cancer Research, ISSN 2218-6751, 04/2016, Volume 5, Issue 2, pp. 208 - 211
Whole brain radiotherapy (WBRT) | Brain metastasis | Non-small cell lung cancer (NSCLC)
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Stopping clinical trials early for futility: retrospective analysis of several randomised clinical studies
by Jitlal, M and Khan, I and Lee, S M and Hackshaw, A
British journal of cancer, ISSN 1745-6215, 09/2012, Volume 107, Issue 6, pp. 910 - A53
Many clinical trials show no overall benefit. We examined futility analyses applied to trials with different effect sizes. Ten randomised cancer trials were... 
Randomized Controlled Trials as Topic - statistics & numerical data | Humans | Clinical Trials, Phase II as Topic - economics | Treatment Outcome | Neoplasms - drug therapy | Patient Selection | Early Termination of Clinical Trials | Clinical Trials, Phase II as Topic - statistics & numerical data | Medical Futility | Neoplasms - radiotherapy | Randomized Controlled Trials as Topic - economics | Retrospective Studies | Odds Ratio | Research Design
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Addition of apatorsen, an inhibitor of Hsp27, to first-line gemcitabine/carboplatin in advanced squamous cell lung cancer: Design of the Cedar study
by Schmid, Peter and Muthukumar, Dakshinmoorthy and Blackhall, Fiona Helen and Lester, Jason Francis and Khan, Sarah and Illsley, Marianne and Adams, Joss and Garcia-Alonso, Angel and MacDonald-Smith, Carey and Lee, Siow Ming and Jacobs, Cindy and Middleton, Gary William and James, Christine and Mousa, Kelly and Sarker, Shah-Jalal and Lim, Louise
Journal of Clinical Oncology, ISSN 0732-183X, 05/2015, Volume 33, Issue 15_suppl, pp. TPS8111 - TPS8111
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Tracking the Evolution of Non–Small-Cell Lung Cancer
by Jamal-Hanjani, Mariam and Wilson, Gareth A and McGranahan, Nicholas and Birkbak, Nicolai J and Watkins, Thomas B.K and Veeriah, Selvaraju and Shafi, Seema and Johnson, Diana H and Mitter, Richard and Rosenthal, Rachel and Salm, Max and Horswell, Stuart and Escudero, Mickael and Matthews, Nik and Rowan, Andrew and Chambers, Tim and Moore, David A and Turajlic, Samra and Xu, Hang and Lee, Siow-Ming and Forster, Martin D and Ahmad, Tanya and Hiley, Crispin T and Abbosh, Christopher and Falzon, Mary and Borg, Elaine and Marafioti, Teresa and Lawrence, David and Hayward, Martin and Kolvekar, Shyam and Panagiotopoulos, Nikolaos and Janes, Sam M and Thakrar, Ricky and Ahmed, Asia and Blackhall, Fiona and Summers, Yvonne and Shah, Rajesh and Joseph, Leena and Quinn, Anne M and Crosbie, Phil A and Naidu, Babu and Middleton, Gary and Langman, Gerald and Trotter, Simon and Nicolson, Marianne and Remmen, Hardy and Kerr, Keith and Chetty, Mahendran and Gomersall, Lesley and Fennell, Dean A and Nakas, Apostolos and Rathinam, Sridhar and Anand, Girija and Khan, Sajid and Russell, Peter and Ezhil, Veni and Ismail, Babikir and Irvin-Sellers, Melanie and Prakash, Vineet and Lester, Jason F and Kornaszewska, Malgorzata and Attanoos, Richard and Adams, Haydn and Davies, Helen and Dentro, Stefan and Taniere, Philippe and O’Sullivan, Brendan and Lowe, Helen L and Hartley, John A and Iles, Natasha and Bell, Harriet and Ngai, Yenting and Shaw, Jacqui A and Herrero, Javier and Szallasi, Zoltan and Schwarz, Roland F and Stewart, Aengus and Quezada, Sergio A and Le Quesne, John and Van Loo, Peter and Dive, Caroline and Hackshaw, Allan and Swanton, Charles and TRACERx Consortium
The New England Journal of Medicine, ISSN 0028-4793, 06/2017, Volume 376, Issue 22, pp. 2109 - 2121
Distinct genes are mutated in different regions of a single patient’s tumor. Point mutations seem to have less adverse effect on relapse-free survival than... 
HETEROGENEITY | WIDESPREAD | MUTATIONAL PROCESSES | MEDICINE, GENERAL & INTERNAL | ADENOCARCINOMAS | PATTERNS | CHROMOSOMAL INSTABILITY | Lung Neoplasms - genetics | Prognosis | Prospective Studies | Carcinoma, Non-Small-Cell Lung - genetics | Lung Neoplasms - mortality | Humans | Risk Factors | Male | Phylogeny | Carcinoma, Non-Small-Cell Lung - mortality | Genetic Heterogeneity | DNA Copy Number Variations | Exome | Disease-Free Survival | Female | Neoplasm Recurrence, Local - genetics | Mutation | Chromosomal Instability | Sequence Analysis, DNA - methods | Evolution, Molecular | Lung cancer, Non-small cell | Chromosomes | Research | Medical research | Chromatin | Epidermal growth factor receptors | Transcription | p53 Protein | Lung cancer | DNA damage | Non-small cell lung carcinoma | Oncology | Genomes | Multivariate analysis | DNA repair | Survival | Cyclin-dependent kinase 4 | Genomic instability | Pathology | Census | Lungs | Evolution | Death | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
by Soria, Jean-Charles and Ohe, Yuichiro and Vansteenkiste, Johan and Reungwetwattana, Thanyanan and Chewaskulyong, Busyamas and Lee, Siow-Ming and Lee, Ki Hyeong and Dechaphunkul, Arunee and Imamura, Fumio and Nogami, Naoyuki and Kurata, Takayasu and Okamoto, Isamu and Zhou, Caicun and Cho, Byoung Chul and Cho, Eun Kyung and Cheng, Ying and Voon, Pei Jye and Planchard, David and Su, Wu-Chou and Gray, Jhanelle E and Hodge, Rachel and Marotti, Marcelo and Rukazenkov, Yuri and Ramalingam, Suresh S and FLAURA Investigators
The New England Journal of Medicine, ISSN 0028-4793, 01/2018, Volume 378, Issue 2, pp. 113 - 125
In 556 patients with previously untreated lung cancer bearing EGFR mutations, osimertinib and the first-generation EGFR inhibitors erlotinib and gefitinib had... 
1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | PHASE-III | ACQUIRED-RESISTANCE | OPEN-LABEL | CNS RESPONSE | AZD9291 | CHEMOTHERAPY | ERLOTINIB | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Gefitinib | Lung Neoplasms - genetics | Double-Blind Method | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Survival Rate | Piperazines - therapeutic use | Carcinoma, Non-Small-Cell Lung - mortality | Piperazines - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Aged | Erlotinib Hydrochloride - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Treatment outcome | Cancer patients | Care and treatment | Lung cancer, Non-small cell | Analysis | Tyrosine | Medical research | Epidermal growth factor receptors | Lung cancer | Clinical trials | Non-small cell lung carcinoma | Oncology | Metastasis | Gene deletion | Patients | Cancer therapies | Clinical outcomes | Chemotherapy | Epidermal growth factor | Clonal deletion | Protein-tyrosine kinase receptors | Protein-tyrosine kinase | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Spatial and temporal diversity in genomic instability processes defines lung cancer evolution
by De Bruin, Elza C and McGranahan, Nicholas and Mitter, Richard and Salm, Max and Wedge, David C and Yates, Lucy and Jamal-Hanjani, Mariam and Shafi, Seema and Murugaesu, Nirupa and Rowan, Andrew J and Grönroos, Eva and Muhammad, Madiha A and Horswell, Stuart and Gerlinger, Marco and Varela, Ignacio and Jones, David and Marshall, John and Voet, Thierry and Van Loo, Peter and Rassl, Doris M and Rintoul, Robert C and Janes, Sam M and Lee, Siow-Ming and Forster, Martin and Ahmad, Tanya and Lawrence, David and Falzon, Mary and Capitanio, Arrigo and Harkins, Timothy T and Lee, Clarence C and Tom, Warren and Teefe, Enock and Chen, Shann-Ching and Begum, Sharmin and Rabinowitz, Adam and Phillimore, Benjamin and Spencer-Dene, Bradley and Stamp, Gordon and Szallasi, Zoltan and Matthews, Nik and Stewart, Aengus and Campbell, Peter and Swanton, Charles
Science, ISSN 0036-8075, 10/2014, Volume 346, Issue 6206, pp. 251 - 256
Spatial and temporal dissection of the genomic changes occurring during the evolution of human non-small cell lung cancer (NSCLC) may help elucidate the basis... 
HETEROGENEITY | MUTAGENESIS | SIGNATURES | ADENOCARCINOMA | MULTIDISCIPLINARY SCIENCES | RESISTANCE | PATTERNS | MUTATIONS | REARRANGEMENTS | CHROMOSOMAL INSTABILITY | Lung Neoplasms - genetics | Smoking - adverse effects | Genomic Instability | Translocation, Genetic | Prognosis | Lung Neoplasms - chemically induced | Carcinoma, Non-Small-Cell Lung - genetics | Cytidine Deaminase - genetics | Humans | Carcinoma, Non-Small-Cell Lung - diagnosis | Gene Dosage | Genetic Heterogeneity | Carcinogens - toxicity | APOBEC-1 Deaminase | Neoplasm Recurrence, Local - genetics | Mutation | Tumor Cells, Cultured | Lung Neoplasms - diagnosis | Carcinoma, Non-Small-Cell Lung - chemically induced | Evolution, Molecular | Development and progression | Genetic aspects | Research | Lung cancer, Non-small cell | Carcinogenesis | Cancer | Oncology | Chemotherapy | Genetic diversity | Genomics | Lung cancer | Tumors | Index Medicus | Mutations | Alterations | Lungs | Instability | Evolution | Genomes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data
by Antonio Rossi and Massimo Di Maio and Paolo Chiodini and Robin Michael Rudd and Hiroaki Okamoto and Dimosthenis Vasilios Skarlos and Martin Früh and Wendi Qian and Tomohide Tamura and Epaminondas Samantas and Taro Shibata and Francesco Perrone and Ciro Gallo and Cesare Gridelli and Olga Martelli and Siow-Ming Lee
Journal of Clinical Oncology, ISSN 0732-183X, 05/2012, Volume 30, Issue 14, pp. 1692 - 1698
Purpose Since treatment efficacy of cisplatin-or carboplatin-based chemotherapy in the first-line treatment of small-cell lung cancer (SCLC) remains... 
TRIAL | IRRADIATION | ETOPOSIDE | ONCOLOGY-GROUP | QUALITY | ONCOLOGY | RANDOMIZED PHASE-III | CISPLATIN/ETOPOSIDE | TIME | OVARIAN-CANCER | FAILURE | Lung Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Cisplatin - administration & dosage | Carboplatin - adverse effects | Neoplasm Invasiveness - pathology | Statistics, Nonparametric | Aged, 80 and over | Adult | Female | Carcinoma, Non-Small-Cell Lung - pathology | Risk Assessment | Kaplan-Meier Estimate | Carboplatin - administration & dosage | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Randomized Controlled Trials as Topic | Disease-Free Survival | Survival Analysis | Cisplatin - adverse effects | Italy | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: A meta-analysis
by Lee, Chee Khoon and Brown, Chris and Gralla, Richard J and Hirsh, Vera and Thongprasert, Sumitra and Tsai, Chun-Ming and Tan, Eng Huat and Ho, James Chung-Man and Chu, Da Tong and Zaatar, Adel and Osorio Sanchez, Jemela Anne and Vu, Vu Van and Au, Joseph Siu Kie and Inoue, Akira and Lee, Siow Ming and Gebski, Val and Yang, James Chih-Hsin
Journal of the National Cancer Institute, ISSN 0027-8874, 05/2013, Volume 105, Issue 9, pp. 595 - 605
Background The epidermal growth factor receptor (EGFR) signaling pathway is crucial for regulating tumorigenesis and cell survival and may be important in the... 
TYROSINE KINASE INHIBITORS | PHASE-III TRIAL | 1ST-LINE TREATMENT | GEFITINIB | ONCOLOGY | CLINICAL-TRIALS | 2ND-LINE TREATMENT | OPEN-LABEL | NEVER-SMOKERS | ERLOTINIB | CHEMOTHERAPY | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Lung Neoplasms - metabolism | Middle Aged | Male | Cisplatin - administration & dosage | Female | Quinazolines - administration & dosage | Deoxycytidine - administration & dosage | Carcinoma, Non-Small-Cell Lung - metabolism | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Randomized Controlled Trials as Topic | Disease-Free Survival | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Survival Analysis | Glutamates - administration & dosage | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Deoxycytidine - analogs & derivatives | Guanine - administration & dosage | Protein-Tyrosine Kinases - antagonists & inhibitors | Usage | Gene mutations | Analysis | Patient outcomes | Physiological aspects | Development and progression | Genetic aspects | Research | Lung cancer, Non-small cell | Meta-analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Anti-angiogenesis drugs in lung cancer: PRO/CON DEBATE
by Lee, Siow Ming and Baas, Paul and Wakelee, Heather
Respirology, ISSN 1323-7799, 04/2010, Volume 15, Issue 3, pp. 387 - 392
Anti-angiogenesis | Lung cancer | VEGF | Bevacizumab
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial
by Lee, Siow Ming, Prof and Khan, Iftekhar, MSc and Upadhyay, Sunil, MD and Lewanski, Conrad, FRCP and Falk, Stephen, MD and Skailes, Geraldine, FRCR and Marshall, Ernie, MD and Woll, Penella J, Prof and Hatton, Matthew, FRCR and Lal, Rohit, MRCP and Jones, Richard, FRCR and Toy, Elizabeth, FRCR and Chao, David, DPhil and Middleton, Gary, MD and Bulley, Sue, SRN and Ngai, Yenting, BSc and Rudd, Robin, MD and Hackshaw, Allan, Prof and Boshoff, Chris, Prof
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 11, pp. 1161 - 1170
Summary Background Many patients with advanced non-small-cell lung cancer (NSCLC) receive only active supportive care because of poor performance status or... 
Hematology, Oncology and Palliative Medicine | GROWTH-FACTOR RECEPTOR | PERFORMANCE STATUS | STANDARD CHEMOTHERAPY | CETUXIMAB | RASH | MULTICENTER | GEFITINIB | ONCOLOGY | OPEN-LABEL | COMBINATION | METASTATIC COLORECTAL-CANCER | Carcinoma, Non-Small-Cell Lung - pathology | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Double-Blind Method | Drug-Related Side Effects and Adverse Reactions - chemically induced | Humans | Kaplan-Meier Estimate | Antineoplastic Combined Chemotherapy Protocols | Lung Neoplasms - pathology | Male | Treatment Outcome | Protein Kinase Inhibitors - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Quinazolines - adverse effects | Aged, 80 and over | Female | Quinazolines - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Drug-Related Side Effects and Adverse Reactions - classification | Receptor, Epidermal Growth Factor | Cancer patients | Care and treatment | Chemotherapy | Erlotinib | Comorbidity | Oncology, Experimental | Clinical trials | Product development | Research | Lung cancer, Non-small cell | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study
by Jamal-Hanjani, Mariam and Hackshaw, Alan and Ngai, Yenting and Shaw, Jacqueline and Dive, Caroline and Quezada, Sergio and Middleton, Gary and de Bruin, Elza and Le Quesne, John and Shafi, Seema and Falzon, Mary and Horswell, Stuart and Blackhall, Fiona and Khan, Iftekhar and Janes, Sam and Nicolson, Marianne and Lawrence, David and Forster, Martin and Fennell, Dean and Lee, Siow-Ming and Lester, Jason and Kerr, Keith and Muller, Salli and Iles, Natasha and Smith, Sean and Murugaesu, Nirupa and Mitter, Richard and Salm, Max and Stuart, Aengus and Matthews, Nik and Adams, Haydn and Ahmad, Tanya and Attanoos, Richard and Bennett, Jonathan and Birkbak, Nicolai Juul and Booton, Richard and Brady, Ged and Buchan, Keith and Capitano, Arrigo and Chetty, Mahendran and Cobbold, Mark and Crosbie, Philip and Davies, Helen and Denison, Alan and Djearman, Madhav and Goldman, Jacki and Haswell, Tom and Joseph, Leena and Kornaszewska, Malgorzata and Krebs, Matthew and Langman, Gerald and MacKenzie, Mairead and Millar, Joy and Morgan, Bruno and Naidu, Babu and Nonaka, Daisuke and Peggs, Karl and Pritchard, Catrin and Remmen, Hardy and Rowan, Andrew and Shah, Rajesh and Smith, Elaine and Summers, Yvonne and Taylor, Magali and Veeriah, Selvaraju and Waller, David and Wilcox, Ben and Wilcox, Maggie and Woolhouse, Ian and McGranahan, Nicholas and Swanton, Charles
PLoS Biology, ISSN 1544-9173, 2014, Volume 12, Issue 7, pp. 1 - 7
The importance of intratumour genetic and functional heterogeneity is increasingly recognised as a driver of cancer progression and survival outcome.... 
CLONAL SELECTION | INSTABILITY | BIOCHEMISTRY & MOLECULAR BIOLOGY | INTRATUMOR HETEROGENEITY | ADENOCARCINOMAS | BIOLOGY | ACQUIRED-RESISTANCE | PROGNOSTIC-SIGNIFICANCE | MUTATIONAL EVOLUTION | SOMATIC MUTATIONS | BREAST | EGFR | Lung Neoplasms - genetics | Neoplasm Metastasis | Antigens, Neoplasm | Biomarkers, Tumor - analysis | Carcinoma, Non-Small-Cell Lung - genetics | Humans | Drug Resistance, Neoplasm | Treatment Outcome | Longitudinal Studies | Disease Progression | Medical research | Biomedical research | Lung cancer | Genomes | Metastasis | Drug resistance | Patients | Medicine | Studies | Biopsy | Deoxyribonucleic acid | DNA | Evolution | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights